Summary
DRUG maker Shire Pharmaceuticals struck back against government plans to save money by denying treatment to thousands of Alzheimer's sufferers.
The UK's National Institute for Clinical Excellence, which makes healthcare recommendations to the NHS, said Alzheimer's drugs including Shire's Reminyl were too expensive at around Pounds 2.50 a day.See the full content of this document
Extract
Alzheimer's Plan a Mistake, Says Shire
But Shire boss Matthew Emmens said: 'We...
See the full content of this document
Sponsored links
